CONMED Corporation(CNMD) Stock Research - Grey Stern Research
Loading...

CONMED Corporation (CNMD) Stock Analysis

$74.72 (-1.03%)

CNMD Financial Performance


Use the table below to view CONMED Corporation's financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q1 - 2024

Metric Value Ranking among Peers
Price $75.50 -
52 Week Low $61.05 -
52 Week High $138.47 -
Market Cap $2.3 Billion 7/17
Gross Margin 55% 14/17
Profit Margin 6% 1/17
EBITDA margin 11% 5/17
Q1 - 2024 Revenue $312.3 Million 5/17
Q1 - 2024 Earnings $19.7 Million 2/17
Q1 - 2024 Free Cash Flow $27.1 Million 3/17
Trailing 4 Quarters Revenue $1.3 Billion 4/17
Trailing 4 Quarters Earnings $82.3 Million 4/17
Quarterly Earnings Growth 984% 1/17
Annual Earnings Growth 1% 6/17
Quarterly Revenue Growth 6% 13/17
Annual Revenue Growth 20% 7/17
Cash On Hand $33.9 Million 12/17
Short Term Debt $692,000 12/17
Long Term Debt $990.1 Million 2/17

CONMED Corporation Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare CONMED Corporation's metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 28.24 5/17
PS 1.84 15/17
PB 2.72 10/17
PC 68.69 4/17
Liabilities to Equity 1.70 2/17
ROA 0.04 2/17
ROE 0.10 2/17
Current Ratio 1.59 16/17
Quick Ratio 0.02 16/17
Long Term Debt to Equity 1.16 1/17
Debt to Equity 1.16 1/17
Burn Rate 1.69 12/17
Cash to Cap 0.01 14/17
CCR 1.37 3/17
EV to EBITDA 93.75 4/17
EV to Revenue 2.60 13/17

Company Details

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. It offers orthopedic surgery products, including TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and PopLok Knotless Suture Anchors, which provide unique clinical solutions to orthopedic surgeons for the repair of soft tissue injuries, as well as supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including diagnostic and therapeutic products for use in gastroenterology procedures, and products for the treatment of diseases of the biliary structures, as well as cardiac monitoring products comprising ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.

CEO: Mr. Curt Hartman

Website: https://www.conmed.com

Address: 525 French Road Utica, NEW YORK

Exchange: New York Stock Exchange

Industry: Medical Devices

CONMED Corporation Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to CONMED Corporation. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Glaukos Corporation GKOS $5.5 Billion
LivaNova PLC LIVN $3.4 Billion
NuVasive, Inc. NUVA $2.1 Billion
STERIS plc STE $23.0 Billion
Globus Medical, Inc. GMED $8.7 Billion
iRhythm Technologies, Inc. IRTC $2.9 Billion
Integer Holdings Corporation ITGR $4.1 Billion
Heska Corporation HSKA $1.3 Billion
Surmodics, Inc. SRDX $493.7 Million
Orthofix Medical Inc. OFIX $562.9 Million
OrthoPediatrics Corp. KIDS $763.0 Million
Anika Therapeutics, Inc. ANIK $376.6 Million
Alphatec Holdings, Inc. ATEC $1.5 Billion
SI-BONE, Inc. SIBN $614.8 Million
Pulmonx Corporation LUNG $349.3 Million
Sight Sciences, Inc. SGHT $265.7 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
CNMD Income Statements
Quarter Year Revenue Earnings
Q1 2024 $ 312.3 Million $19.7 Million
Q4 2023 $ 327.0 Million $33.1 Million
Q3 2023 $ 304.6 Million $15.8 Million
Q2 2023 $ 317.7 Million $13.7 Million
Q1 2023 $ 295.5 Million $1.8 Million
Q4 2022 $ 250.9 Million $26.6 Million
Q3 2022 $ 275.1 Million $46.2 Million
Q2 2022 $ 277.2 Million -$168.3 Million

View All

CNMD Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q1 2024 $33.9 Million $2.3 Billion $990.8 Million $854.7 Million
Q4 2023 $0 $0 $0 $0
Q3 2023 $30.5 Million $2.3 Billion $1.0 Billion $796.2 Million
Q2 2023 $27.8 Million $2.3 Billion $1.0 Billion $780.2 Million
Q1 2023 $26.5 Million $2.3 Billion $1.1 Billion $752.5 Million
Q4 2022 $28.9 Million $2.3 Billion $1.1 Billion $745.5 Million
Q3 2022 $33.4 Million $2.3 Billion $1.0 Billion $716.3 Million
Q2 2022 $53.2 Million $2.1 Billion $982.7 Million $673.0 Million

View All

CNMD Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q1 2024 $27.1 Million -$2.0 Million $9.6 Million
Q4 2023 $36.0 Million $0 $36.0 Million
Q3 2023 $6,700 $0 $6,700
Q2 2023 $4,300 $0 $4,300
Q1 2023 -$8.1 Million -$4.3 Million -$2.4 Million
Q4 2022 -$17.3 Million -$5.7 Million -$4.4 Million
Q3 2022 $28.9 Million -$16.1 Million -$19.8 Million
Q2 2022 $9.7 Million -$9.4 Million $28.3 Million

View All